# Add-on Dupilumab for AFRS as Postoperative Therapy (ADAPT)

> **NCT05545072** · PHASE3 · TERMINATED · sponsor: **Emory University** · enrollment: 5 (actual)

## Conditions studied

- Allergic Fungal Rhinosinusitis

## Interventions

- **DRUG:** Dupilumab
- **DRUG:** Placebo
- **DRUG:** Intranasal Corticosteroid Sprays (INCS)

## Key facts

- **NCT ID:** NCT05545072
- **Lead sponsor:** Emory University
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2023-10-26
- **Primary completion:** 2024-07-10
- **Final completion:** 2024-07-10
- **Target enrollment:** 5 (ACTUAL)
- **Why stopped:** The study was terminated due to funding ending.
- **Last updated:** 2025-05-08

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05545072

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05545072, "Add-on Dupilumab for AFRS as Postoperative Therapy (ADAPT)". Retrieved via AI Analytics 2026-08-11 from https://api.ai-analytics.org/clinical/NCT05545072. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*